Barclays
TEVA icon

Barclays’s Teva Pharmaceuticals TEVA Stock Holding History

Barclays’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,219,600
Closed -$24.6M – 5682
2025
Q3 		$24.6M Buy
+1,219,600
New +$21.4M 0.01% 1109
2024
Q1 		– Sell
-200,000
Closed -$2.09M – 5359
2023
Q4 		$2.09M Buy
+200,000
New +$1.87M ﹤0.01% 2887
2023
Q2 		– Sell
-1,278,900
Closed -$11.3M – 5067
2023
Q1 		$11.3M Buy
+1,278,900
New +$12.6M 0.01% 1105
2022
Q1 		– Sell
-455,200
Closed -$3.65M – 5589
2021
Q4 		$3.65M Buy
455,200
+434,000
+2,047% +$3.92M ﹤0.01% 1940
2021
Q3 		$206K Hold
21,200
– – ﹤0.01% 3608
2021
Q2 		$210K Hold
21,200
– – ﹤0.01% 3530
2021
Q1 		$245K Sell
21,200
-12,500
-37% -$143K ﹤0.01% 3611
2020
Q4 		$325K Hold
33,700
– – ﹤0.01% 3506
2020
Q3 		$304K Sell
33,700
-1,200
-3% -$12.7K ﹤0.01% 3571
2020
Q2 		$430K Sell
34,900
-755,500
-96% -$8.54M ﹤0.01% 3460
2020
Q1 		$7.1M Sell
790,400
-3,797,100
-83% -$38.9M 0.01% 1216
2019
Q4 		$45M Buy
4,587,500
+3,692,700
+413% +$33M 0.02% 550
2019
Q3 		$6.16M Buy
894,800
+140,200
+19% +$1.07M ﹤0.01% 1671
2019
Q2 		$6.96M Buy
754,600
+429,700
+132% +$5.18M ﹤0.01% 1578
2019
Q1 		$5.09M Sell
324,900
-344,600
-51% -$6.08M ﹤0.01% 1659
2018
Q4 		$10.3M Sell
669,500
-316,200
-32% -$6.48M 0.01% 1136
2018
Q3 		$21.2M Sell
985,700
-449,200
-31% -$10.4M 0.01% 821
2018
Q2 		$34.9M Sell
1,434,900
-679,200
-32% -$13.9M 0.03% 507
2018
Q1 		$36.1M Buy
2,114,100
+209,300
+11% +$4.09M 0.03% 547
2017
Q4 		$36.1M Sell
1,904,800
-409,900
-18% -$6.17M 0.03% 539
2017
Q3 		$40.7M Buy
2,314,700
+689,500
+42% +$15.5M 0.04% 378
2017
Q2 		$54M Buy
1,625,200
+694,100
+75% +$21.5M 0.06% 258
2017
Q1 		$29.9M Sell
931,100
-39,400
-4% -$1.34M 0.03% 407
2016
Q4 		$35.2M Buy
970,500
+459,600
+90% +$18.3M 0.04% 372
2016
Q3 		$23.5M Sell
510,900
-1,586,500
-76% -$82.8M 0.03% 481
2016
Q2 		$105M Buy
2,097,400
+1,677,200
+399% +$89.3M 0.14% 116
2016
Q1 		$22.3M Sell
420,200
-717,700
-63% -$42.1M 0.03% 435
2015
Q4 		$74M Sell
1,137,900
-33,200
-3% -$2.05M 0.09% 190
2015
Q3 		$65.6M Buy
1,171,100
+721,100
+160% +$46.8M 0.08% 212
2015
Q2 		$26.6M Buy
450,000
+44,300
+11% +$2.73M 0.03% 517
2015
Q1 		$25.2M Sell
405,700
-116,100
-22% -$6.75M 0.03% 576
2014
Q4 		$29.7M Buy
521,800
+42,600
+9% +$2.37M 0.03% 561
2014
Q3 		$25.4M Buy
479,200
+24,800
+5% +$1.31M 0.02% 602
2014
Q2 		$23.6M Sell
454,400
-753,400
-62% -$38.5M 0.03% 621
2014
Q1 		$62.8M Buy
1,207,800
+196,700
+19% +$9.09M 0.07% 240
2013
Q4 		$40.4M Buy
1,011,100
+179,100
+22% +$7.05M 0.04% 418
2013
Q3 		$30.8M Buy
832,000
+43,700
+6% +$1.7M 0.04% 467
2013
Q2 		$30.9M Buy
+788,300
New +$30.7M 0.04% 429

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's TEVA Position: Q1 2026 in Review

Barclays increased its Teva Pharmaceuticals (TEVA) stake by 0.36% in Q1 2026, buying an estimated $161K and bringing the position to 1,400,671 shares worth $42.2M. The position accounts for 0.01% of the portfolio, ranked #792.

Barclays first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q2 2016. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Barclays held 1,400,671 shares of Teva Pharmaceuticals worth $42.2M as of Q1 2026.
  • Barclays bought 5,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $161K.
  • Teva Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #792 holding.
  • Barclays first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Teva Pharmaceuticals position peaked at $160M in Q2 2016.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.